
    
      Subjects with measurable disease will be assessed for response after every 2 cycles of
      therapy using RECIST 1.1 criteria. In addition, progression free survival (PFS), overall
      survival (OS) and exploratory biomarkers, imaging, and thrombotic risk parameters will be
      evaluated.
    
  